Your browser doesn't support javascript.
loading
Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial.
Acheson, Liam S; Ezard, Nadine; Lintzeris, Nicholas; Dunlop, Adrian; Brett, Jonathan; Rodgers, Craig; Gill, Anthony; Christmass, Michael; McKetin, Rebecca; Farrell, Michael; Shoptaw, Steve; Siefried, Krista J.
Affiliation
  • Acheson LS; The National Drug and Alcohol Research Centre (NDARC), the University of New South Wales, Sydney, Australia; Alcohol and Drug Service, St Vincent's Hospital Sydney, Sydney, Australia; The National Centre for Clinical Research on Emerging Drugs (NCCRED), c/o the University of New South Wales, Sydney,
  • Ezard N; The National Drug and Alcohol Research Centre (NDARC), the University of New South Wales, Sydney, Australia; Alcohol and Drug Service, St Vincent's Hospital Sydney, Sydney, Australia; The National Centre for Clinical Research on Emerging Drugs (NCCRED), c/o the University of New South Wales, Sydney,
  • Lintzeris N; New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), NSW, Australia; The Langton Centre, South East Sydney Local Health District, Sydney, Australia; Discipline of Addiction Medicine, the University of Sydney, Sydney, Australia.
  • Dunlop A; New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), NSW, Australia; Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, Australia; School of Medicine and Public Health, the University of Newcastle, Newcastle, Australia.
  • Brett J; Clinical Pharmacology and Toxicology, St Vincent's Hospital Sydney, Sydney, Australia; St. Vincent's Clinical School, the University of New South Wales, Sydney, Australia.
  • Rodgers C; Alcohol and Drug Service, St Vincent's Hospital Sydney, Sydney, Australia.
  • Gill A; Alcohol and Drug Service, St Vincent's Hospital Sydney, Sydney, Australia.
  • Christmass M; Next Step Drug and Alcohol Services, Perth, Australia; National Drug Research Institute, Curtin University, Perth, Australia.
  • McKetin R; The National Drug and Alcohol Research Centre (NDARC), the University of New South Wales, Sydney, Australia.
  • Farrell M; The National Drug and Alcohol Research Centre (NDARC), the University of New South Wales, Sydney, Australia.
  • Shoptaw S; Department of Family Medicine, The University of California Los Angeles, Los Angeles, USA.
  • Siefried KJ; The National Drug and Alcohol Research Centre (NDARC), the University of New South Wales, Sydney, Australia; Alcohol and Drug Service, St Vincent's Hospital Sydney, Sydney, Australia; The National Centre for Clinical Research on Emerging Drugs (NCCRED), c/o the University of New South Wales, Sydney,
Drug Alcohol Depend ; 241: 109692, 2022 Dec 01.
Article in En | MEDLINE | ID: mdl-36399936
ABSTRACT

BACKGROUND:

There is no effective treatment for methamphetamine withdrawal. This study aimed to determine the feasibility and safety of a tapering dose of lisdexamfetamine for the treatment of acute methamphetamine (MA) withdrawal.

METHODS:

Open-label, single-arm pilot study, in an inpatient drug and alcohol withdrawal unit assessing a tapering dose of oral lisdexamfetamine dimesylate commencing at 250 mg once daily, reducing by 50 mg per day to 50 mg on Day 5. Measures were assessed daily (days 0-7) with 21-day telephone follow-up. Feasibility was measured by the time taken to enrol the sample. Safety was the number of adverse events (AEs) by system organ class. Retention was the proportion to complete treatment. Other measures included the Treatment Satisfaction Questionnaire for Medication (TSQM), the Amphetamine Withdrawal Questionnaire and craving (Visual Analogue Scale).

RESULTS:

Ten adults seeking inpatient treatment for MA withdrawal (9 male, median age 37.1 years [IQR 31.7-41.9]), diagnosed with MA use disorder were recruited. The trial was open for 126 days; enroling one participant every 12.6 days. Eight of ten participants completed treatment (Day 5). Two participants left treatment early. There were no treatment-related serious adverse events (SAEs). Forty-seven AEs were recorded, 17 (36%) of which were potentially causally related, all graded as mild severity. Acceptability of the study drug by TSQM was rated at 100% at treatment completion. Withdrawal severity and craving reduced through the admission.

CONCLUSION:

A tapering dose regimen of lisdexamfetamine was safe and feasible for the treatment of acute methamphetamine withdrawal in an inpatient setting.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Substance Withdrawal Syndrome / Amphetamine-Related Disorders / Alcoholism / Central Nervous System Stimulants / Methamphetamine Limits: Adult / Humans / Male Language: En Journal: Drug Alcohol Depend Year: 2022 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Substance Withdrawal Syndrome / Amphetamine-Related Disorders / Alcoholism / Central Nervous System Stimulants / Methamphetamine Limits: Adult / Humans / Male Language: En Journal: Drug Alcohol Depend Year: 2022 Document type: Article